CTXR Company Profile and Key Details
Citius Pharmaceuticals, Inc.
CTXR Stock Price Chart
Stock Price Today
Citius Pharmaceuticals, Inc. (CTXR) stock declined over -3.08%, trading at $3.15 on NASDAQ, down from the previous close of $3.25. The stock opened at $3.25, fluctuating between $3.12 and $3.25 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Company Information
| Employees | 22 |
| Beta | 1.66 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | September |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) stock price is $3.15 in the last trading session. During the trading session, CTXR stock reached the peak price of $3.25 while $3.12 was the lowest point it dropped to. The percentage change in CTXR stock occurred in the recent session was -3.08% while the dollar amount for the price change in CTXR stock was -$0.10.
The NASDAQ listed CTXR is part of Biotechnology industry that operates in the broader Healthcare sector. Citius Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Myron S. Czuczman M.D.
Executive Vice President & Chief Medical Officer
Mr. Gary F. Talarico
Executive Vice President of Operations
Mr. Kelly Creighton Ph.D.
Executive Vice President of Chemistry, Manufacturing & Controls
Mr. Nikolas Burlew
Executive Vice President of Quality Assurance
Mr. Myron Z. Holubiak
Co-Founder & Executive Vice Chairman
Ms. Ilanit Allen
Vice President of Investor Relations & Corporation Communications
Mr. Leonard L. Mazur
Co-Founder, Chief Executive Officer, Chairman & Sec.
Mr. Jaime Bartushak
Chief Bus. Officer, Chief Financial Officer & Chief Accounting Officer
Dr. Alan Lader Ph.D.
Senior Vice President and Head of Clinical Operations & Quality Assurance
Mr. Dhananjay G. Wadekar
Senior Vice President of Bus. Strategy
CTXR's closing price is 29.1% higher than its 52-week low of $2.44 where as its distance from 52-week high of $26.75 is -88.22%.
Number of CTXR employees currently stands at 22.
Official Website of CTXR is: https://www.citiuspharma.com
CTXR could be contacted at phone 908 967 6677 and can also be accessed through its website. CTXR operates from 11 Commerce Drive, Cranford, NJ 07016, United States.
CTXR stock volume for the day was 74.67K shares. The average number of CTXR shares traded daily for last 3 months was 284.45K.
The market value of CTXR currently stands at $26.68M with its latest stock price at $3.15 and 8.47M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com